GlassScriptPhysician profile
Nikola Ragusa
NPI 1568625192
$81,083.94
in general payments reported to CMS, 2019-2025
27 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $28K · 2021: $11K · 2022: $8,559 · 2023: $2,228 · 2024: $2,327 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,399 · Honoraria: $1,500 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,398.75 |
| Honoraria | $1,500.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $50,687.26 | 2019-2021 | |
| Sight Sciences, INC. | $7,634.34 | 2019-2022 | |
| New World Medical,INC. | $6,224.16 | 2019-2024 | Clearpath, Ahmed Glaucoma Valve, Streamline |
| Ivantis, INC | $4,105.51 | 2019-2021 | |
| Alcon Vision LLC | $4,014.93 | 2019-2025 | Rocklatan, Eysuvis, Clareon |
| Lensar, INC. | $3,545.09 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $1,647.06 | 2022-2025 | Envista Mx60 Iol, Toric, Xiidra |
| Novartis Pharmaceuticals Corporation | $753.90 | 2019-2023 | |
| Rayner Intraocular Lenses Limited | $376.79 | 2021-2024 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Allergan, INC. | $349.26 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $311.52 | 2019-2025 | Tecnis Simplicity, Tecnis Iol, Catalys System |
| Oyster Point Pharma, INC. | $309.16 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Abbvie INC. | $210.16 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $138.98 | 2023 | Acthar |
| Shire North American Group INC | $129.00 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $106.83 | 2024-2025 | Vevye |
| Sun Pharmaceutical Industries INC. | $96.68 | 2019-2020 | |
| Horizon Therapeutics Plc | $77.44 | 2020-2023 | Tepezza |
| Amgen INC. | $68.51 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $67.05 | 2019-2020 | |
| Ocular Therapeutix, INC. | $64.76 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $43.39 | 2019-2020 | |
| Astellas Pharma US INC | $42.64 | 2025 | Izervay |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Dompe US, INC. | $22.32 | 2025 | Oxervate |
| Biotissue Holdings INC. | $14.07 | 2023 | |
| Optos, INC. | $4.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikola Ragusa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.